Search results for "Adverse effect"

showing 10 items of 1065 documents

Prognostic Value of Microvascular Obstruction and Infarct Size, as Measured by CMR in STEMI Patients

2014

The aim of this study was to evaluate the value of microvascular obstruction (MO) and infarct size as a percentage of left ventricular mass (15%LV), as measured by contrast-enhanced cardiac magnetic resonance, in predicting major cardiovascular adverse events (MACE) at 2 years in patients with ST-segment elevation myocardial infarction reperfused by primary percutaneous coronary intervention. Individual data from 1,025 patients were entered into the pooled analysis. MO was associated with the occurrence of MACE, defined as a composite of cardiac death, congestive heart failure, and myocardial re-infarction (adjusted hazard ratio: 3.74; 95% confidence interval: 2.21 to 6.34). IS% LV >= 25% w…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentmicrovascular obstructionHeart VentriclesMyocardial Infarction[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineRisk Assessmentcardiac magnetic resonance[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicinePercutaneous Coronary InterventionPredictive Value of TestsRecurrenceRisk FactorsInternal medicineCoronary CirculationMedicineinfarct sizeHumansRadiology Nuclear Medicine and imagingMyocardial infarctioncardiovascular diseasesAdverse effectComputingMilieux_MISCELLANEOUSAgedHeart Failurebusiness.industryMicrocirculationMyocardiumHazard ratioPercutaneous coronary interventionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingConfidence intervalTreatment OutcomeRadiology Nuclear Medicine and imagingHeart failureNo reflow phenomenonCardiologyNo-Reflow PhenomenonFemaleprognosisCardiology and Cardiovascular MedicinebusinessMaceJACC. Cardiovascular imaging
researchProduct

Media devices in pre-school children: the recommendations of the Italian pediatric society

2018

Abstract Background Young children are too often exposed to mobile devices (MD) and most of them had their own device. The adverse effects of a early and prolonged exposure to digital technology on pre-school children has been described by several studies. Aim of the study is to analyze the consequences of MD exposure in pre-school children. Methods We analyzed the documented effects of media exposure on children’s mental and physical health. Results According to recent studies, MD may interfere with learning, children development, well being, sleep, sight, listening, caregiver-child relationship. Discussion Pediatricians should be aware of both the beneficial and side effects of MD and giv…

Malemedicine.medical_specialtyTime Factorspreschool childrenMEDLINEGuidelines as TopicPediatricsRisk Assessment03 medical and health sciences0302 clinical medicineChild Development030225 pediatricsSurveys and QuestionnairesMedicineHumansActive listeningMass MediaAdverse effectSocieties Medicalbusiness.industryResearchlcsh:RJ1-570Physical healthlcsh:PediatricsSettore MED/38media deviceProlonged exposureItalyFamily medicineChild PreschoolComputers HandheldWell-beingPre schoolFemaleTelevisionbusinessRisk assessment030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Urinary Incontinence in Chronic Obstructive Pulmonary Disease: A Common Co-morbidity or a Typical Adverse Effect?

2019

Urinary incontinence (UI) is defined as a loss of bladder control and is characterized by the complaint of any involuntary leakage of urine. Evidence suggests that the prevalence of UI is higher in subjects with chronic obstructive pulmonary disease (COPD) than in age-matched controls in both sexes. UI is classified as stress, urge, and mixed, and has a considerable impact on quality of life. However, the prevalence of UI in individuals with COPD is mostly unexplored in clinical research and often underestimated in clinical practice. Interestingly, although the involuntary leakage of a small amount of urine during coughing (e.g., stress UI) is among the most plausible causes of UI in patien…

Malemedicine.medical_specialtyUrinary incontinenceAnticholinergic agentsComorbidity03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesPrevalenceMedicineHumansCOPDPharmacology (medical)030212 general & internal medicineAdverse effectbladderAgedCOPDbusiness.industryUrinary retentionmedicine.diseaseComorbidityClinical researchUrinary IncontinenceQuality of LifeFemaleGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects.

2015

<b><i>Introduction:</i></b> The study aimed to evaluate the efficacy and safety of solifenacin in older patients with overactive bladder (OAB). <b><i>Materials and Methods:</i></b> Observational data on patients aged ≥70 years and the prescribed flexible dose of solifenacin for OAB were collected at 294 offices of German general practitioners. Baseline and week 12 data included type and severity of OAB symptoms, adverse events, quality of life, and change in cognitive function per Mini Mental State Examination (MMSE). <b><i>Results:</i></b> Mean age of 774 patients was 78 ± 6 years. A decrease was observed in all OAB sy…

Malemedicine.medical_specialtyUrinary urgencyUrology030232 urology & nephrologyUrologyMuscarinic Antagonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineCognitionQuality of lifeInternal medicineGermanyMedicineHumansAdverse effectAgedAged 80 and overMini–Mental State ExaminationSolifenacinmedicine.diagnostic_testbusiness.industryUrinary Bladder OveractiveSolifenacin SuccinateMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsTreatment OutcomeOveractive bladderTolerability030220 oncology & carcinogenesisQuality of LifeObservational studyFemalemedicine.symptombusinessCognition Disordersmedicine.drugUrologia internationalis
researchProduct

Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Fai…

2019

Importance Short-term infusions of single vasodilators, usually given in a fixed dose, have not improved outcomes in patients with acute heart failure (AHF). Objective To evaluate the effect of a strategy that emphasized early intensive and sustained vasodilation using individualized up-titrated doses of established vasodilators in patients with AHF. Design, Setting, and Participants Randomized, open-label blinded-end-point trial enrolling 788 patients hospitalized for AHF with dyspnea, increased plasma concentrations of natriuretic peptides, systolic blood pressure of at least 100 mm Hg, and plan for treatment in a general ward in 10 tertiary and secondary hospitals in Switzerland, Bulgari…

Malemedicine.medical_specialtyVasodilator AgentsComorbidityPatient Readmission01 natural sciencesDrug Administration Schedulelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawCause of DeathInternal medicineClinical endpointHumansMedicine030212 general & internal medicine0101 mathematicsAdverse effectAgedCause of deathAged 80 and overHeart Failurebusiness.industry010102 general mathematicsHazard ratioGeneral Medicinemedicine.diseaseHospitalizationBlood pressureHeart failureAcute DiseaseFemalebusinessSacubitril ValsartanJAMA
researchProduct

Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists.

2018

BACKGROUND Although polypharmacy is associated with a negative clinical outcome in various settings and commonly observed in patients receiving oral anticoagulation therapy, evidence on the relevance for the clinical outcome of anticoagulated patients is currently limited. The aim of the study was to investigate the effect of polypharmacy on the clinical outcomes among patients taking phenprocoumon. DESIGN Prospective cohort study. SETTING Regular medical care. PARTICIPANTS Information on 2011 individuals receiving vitamin K antagonists was available for analysis from the prospective multicenter thrombEVAL study. MEASUREMENTS Data were obtained from clinical visits, computer-assisted interv…

Malemedicine.medical_specialtyVitamin KAdministration OralHemorrhage030204 cardiovascular system & hematologyPhenprocoumonCohort Studies03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineGermanyPrevalenceMedicineHumansCumulative incidenceDrug Interactions030212 general & internal medicineInternational Normalized RatioMultiple Chronic ConditionsProspective StudiesRisk factorMortalityProspective cohort studyAdverse effectAgedPolypharmacybusiness.industryMedical recordHazard ratioAnticoagulantsHospitalizationPolypharmacyFemaleGeriatrics and GerontologyDrug Monitoringbusinessmedicine.drugJournal of the American Geriatrics Society
researchProduct

The Mediterranean diet protects against waist circumference enlargement in 12Ala carriers for the PPARgamma gene: 2 years' follow-up of 774 subjects …

2009

The PPARγ gene regulates insulin sensitivity and adipogenesis. The Pro12Ala polymorphism of this gene has been related to fat accumulation. Our aim was to analyse the effects of a 2-year nutritional intervention with Mediterranean-style diets on adiposity in high-cardiovascular risk patients depending on the Pro12Ala polymorphism of the PPARγ gene. The population consisted of a substudy (774 high-risk subjects aged 55–80 years) of the Prevención con Dieta Mediterránea (PREDIMED) randomised trial aimed at assessing the effect of the Mediterranean diet for CVD prevention. There were three nutritional intervention groups: two of them of a Mediterranean-style diet and the third was a control gr…

Malemedicine.medical_specialtyWaistMediterranean dietGenotypePopulationMedicine (miscellaneous)BiologyDiet MediterraneanPolymerase Chain ReactionBody Mass IndexPolymorphism (computer science)Risk FactorsInternal medicineDiabetes mellitusmedicineHumansAlleleeducationAdverse effectAgededucation.field_of_studyNutrition and DieteticsBody WeightSmokingDNAMiddle Agedmedicine.diseasePPAR gammaEndocrinologyAmino Acid SubstitutionCardiovascular DiseasesFemaleWaist CircumferenceBody mass indexPolymorphism Restriction Fragment LengthFollow-Up StudiesThe British journal of nutrition
researchProduct

Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network

2019

Background: Biological therapies have modified the disease course of pediatric inflammatory bowel disease (IBD) and are routinely used in clinical practice. Our observational study aims to evaluate effectiveness and safety of biologics in IBD. Method: Clinical benefit and safety data of 93 children with IBD, receiving biologics (Infliximab – IFX, Adalimumab – ADA, Golimumab – GOL) from January 2013 to December 2017, were extracted from the cohort of the Sicilian Network of IBD. Results: Among 87 children aged 7–17 years (63 Crohn's disease [CD], 24 Ulcerative colitis [UC]), 101 out of 108 biologic treatments were considered. Evaluation of 74 biologic treatments in CD patients at 26, 52, 104…

Malemedicine.medical_specialtyYounger ageAdolescentBiologicEfficacyAnti-Inflammatory AgentsDiseaseInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineCrohn DiseaseGastrointestinal AgentsInternal medicinemedicineHumansAdverse effectChildSicilyRetrospective StudiesBiological ProductsHepatologybusiness.industryGastroenterologyAdalimumabAntibodies MonoclonalBiologics; Child; Efficacy; Inflammatory bowel disease; Safetymedicine.diseaseUlcerative colitisReal life dataInfliximabTreatment Outcome030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyObservational studyColitis UlcerativeFemaleSafetybusiness
researchProduct

Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients

2010

Abstract Background Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is an adverse effect of bisphosphonate treatment with varying reported incidence rates. Methods In two neighboring German cities, prevalence and additional factors of the development of BP-ONJ in multiple myeloma patients with bisphosphonates therapy were recorded using a retrospective (RS) and cross-sectional study (CSS) design. For the RS, all patients treated from Jan. 2000 - Feb. 2006 were contacted by letter. In the CSS, all patients treated from Oct. 2006 - Mar. 2008 had a physical and dental examination. Additionally, a literature review was conducted to evaluate all articles reporting on BP-ONJ prevalen…

Malemedicine.medical_specialtylcsh:Specialties of internal medicineTreatment outcomeClinical NeurologyBisphosphonate-Associated Osteonecrosisstomatognathic systemlcsh:RC581-951medicinePrevalenceHumansAdverse effectGeneral DentistryMultiple myelomaAgedRetrospective StudiesAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryDentistry(all)ResearchOsteonecrosisRetrospective cohort studyMiddle Agedmedicine.diseaseDermatologySurgerystomatognathic diseasesCross-Sectional StudiesTreatment OutcomeOtorhinolaryngologyOral and maxillofacial surgeryHead and neck surgeryFemaleNeurology (clinical)businessMultiple MyelomaBisphosphonate treatmentHead & Face Medicine
researchProduct

Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.

2018

INTRODUCTION Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with monoclonal antibodies has complemented the armamentarium of lipid-lowering therapy (LLT) before the final step of commencing chronic lipoprotein apheresis (LA). Data are scarce on patients who, after escalation of LLT with PCSK9 antibodies, have commenced chronic LA or PCSK9 antibody treatment during ongoing long-term LA. PATIENTS AND METHODS In this study, a cohort of 110 patients with established atherosclerotic cardiovascular disease (ASCVD) due to hypercholesterolemia or concomitant lipoprotein(a)-hyperlipoproteinemia, who received PCSK9 antibodies for the first time during routine care, were consecutivel…

Malemedicine.medical_specialtymedicine.drug_classLipoproteinsHypercholesterolemia030204 cardiovascular system & hematologyMonoclonal antibodyGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansEnzyme InhibitorsAdverse effectbiologybusiness.industryPCSK9PCSK9 InhibitorsAntibodies MonoclonalHematologyGeneral MedicineLipoprotein(a)Cholesterol LDLMiddle AgedAtherosclerosisCombined Modality TherapyLipidsDiscontinuationConcomitantCohortbiology.proteinBlood Component RemovalFemaleAntibodyProprotein Convertase 9business030215 immunologyLipoprotein(a)Journal of clinical apheresis
researchProduct